Altimmune (ALT) Assets (2010 - 2026)

Altimmune (ALT) has 17 years of Assets data on file, last reported at $335.6 million in Q1 2026.

• On a quarterly basis, Assets rose 113.42% year-over-year to $335.6 million in Q1 2026; TTM through Mar 2026 was $335.6 million, a 113.42% increase from a year earlier, with the FY2025 full-year figure at $279.9 million, up 100.95% from the prior year.
• Assets for Q1 2026 stood at $335.6 million, up from $279.9 million in the prior quarter.
• Over the last five years, Assets for ALT reached as high as $335.6 million in Q1 2026 and fell as low as $139.3 million in Q4 2024.
• Historically, Assets has averaged $201.5 million across 5 years, with a median of $190.4 million in 2025.
• Across the five-year window, Assets tumbled 33.87% in 2024 and jumped 113.42% in 2026, its largest moves.
• Year by year, Assets stood at $206.9 million in 2022, then grew by 1.79% to $210.6 million in 2023, then plunged by 33.87% to $139.3 million in 2024, then soared by 100.95% to $279.9 million in 2025, then increased by 19.9% to $335.6 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $335.6 million in Q1 2026, $279.9 million in Q4 2025, and $218.4 million in Q3 2025.